spacer
home > pmps > summer 2019 > accurate, precise microlitre dosing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Accurate, Precise Microlitre Dosing

With an ageing population, development of novel therapeutics, and an increasing number of patients with uncontrolled diabetes, the number of microlitre injections is projected to continue to rise. Since 2006, the number of microlitre injections has dramatically increased due to the availability of new treatments for conditions such as agerelated macular degeneration, diabetic macular edema, and vein occlusions. This trend is projected to be replicated with treatments in dermatology, neurology, and oncology; therapeutic treatments include small molecules, monoclonal antibodies, and cell and gene therapies.

Currently, treatments requiring microlitre dosing are primarily administered using hypodermic or insulin syringes. Delivering with these syringes requires the user to draw up the drug into the syringe and align the plunger seal with an external dose marking. It is widely reported in the literature that all syringes currently used for microlitre dosing (50μl or lower) are inaccurate and imprecise. This is because these syringes, indicated for use in general aspiration and dispensing, are operating at the limits of human capability and at the technical limits of the syringe itself.

Additionally, drugs are often stored in these syringes for several months. The lack of availability of syringe-based injection systems that are more suitable for applications requiring microlitre dosing has resulted in several reports of syringe-related adverse events. This problem is compounded by significant off-label use of both syringes and drugs. In early 2018, several reports of sterile intraocular inflammation were reported in the US associated with the injection of certain lots of Eylea®. Subsequently, Regeneron Pharmaceuticals notified clinicians of their decision to not distribute the hypodermic syringe as part of its drug kit. This was a case where even the short residence time of the drug can result in a serious adverse event. Syringebased delivery systems have severely lagged advancements in drug treatments requiring microlitre dosing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Congruence Medical Solutions, LLC, a privately held company based in Baltimore, Maryland, US, is pioneering development and supply of microlitre injection device systems. Incorporated in 2015, Congruence Medical Solutions has developed its lead product: the Microliter Dosing Syringe (MDS) platform for single microlitre dose applications. With a strong team and a proven track record in injectable drug delivery space, Congruence Medical Solutions aims to supply variants of the MDS and other device platforms to pharma companies. Some variants of the MDS can be available for clinical use as early as January 2020.
spacer
Congruence Medical Solutions
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement